August 13, 2018 / 5:16 AM / 4 days ago

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

(Adds missing first bullet, adds name of drug in headline)

Aug 13 (Reuters) - UCB SA:

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

* GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF INTERMITTENT BOUTS OF INCREASED SEIZURE ACTIVITY

* MIDAZOLAM NASAL SPRAY HAS ALSO BEEN GRANTED FAST TRACK DESIGNATION BY THE US FDA DUE TO THE HIGH UNMET NEED FOR PATIENTS AND CAREGIVERS

* MIDAZOLAM NASAL SPRAY HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) Source text : bit.ly/2KKpyfP Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below